K Olek-Hrab 1 , W Silny , A Dańczak-Pazdrowska , A Osmola-Mańkowska , P A Sadowska , A Polańska , R Gniadecki , D Jenerowicz Show Affiliations »
Abstract
BACKGROUND: Mycosis fungoides (MF) is the most common form of primary cutaneous lymphoma, and is characterized by a malignant proliferation of CD4+ cells. Psoralen ultraviolet A (PUVA) irradiation is the most common treatment for cutaneous lesions. However, PUVA carries the risk of adverse reactions to psoralens and long-term risk of skin cancer. UVA1 may be a safer alternative. AIM: To assess the efficacy of UVA1 phototherapy in patients with early-stage MF (T1-T2). METHODS: Four patients with early-stage MF were treated with 1630-2710 J/cm(2) UVA1 given in 29-40 fractions, and the effect was assessed by clinical examination and by high-resolution ultrasonography. RESULTS: Complete clinical remission of MF was achieved in all cases. CONCLUSIONS: This preliminary report indicates that UVA1 phototherapy might be an efficient treatment for early-stage MF. © The Author(s). CED
BACKGROUND: Mycosis fungoides (MF) is the most common form of primary cutaneous lymphoma , and is characterized by a malignant proliferation of CD4+ cells. Psoralen ultraviolet A (PUVA) irradiation is the most common treatment for cutaneous lesions. However, PUVA carries the risk of adverse reactions to psoralens and long-term risk of skin cancer . UVA1 may be a safer alternative. AIM: To assess the efficacy of UVA1 phototherapy in patients with early-stage MF (T1-T2). METHODS: Four patients with early-stage MF were treated with 1630-2710 J/cm(2) UVA1 given in 29-40 fractions, and the effect was assessed by clinical examination and by high-resolution ultrasonography. RESULTS: Complete clinical remission of MF was achieved in all cases. CONCLUSIONS: This preliminary report indicates that UVA1 phototherapy might be an efficient treatment for early-stage MF. © The Author(s). CED
© 2012 British Association of Dermatologists.
Entities: Chemical
Disease
Species
Mesh： See more »
Year: 2012
PMID： 23082901 DOI： 10.1111/ced.12001
Source DB: PubMed Journal: Clin Exp Dermatol ISSN： 0307-6938 Impact factor: 3.470